在线国产一区二区_成人黄色片在线观看_国产成人免费_日韩精品免费在线视频_亚洲精品美女久久_欧美一级免费在线观看

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Europe

UK approves antiviral treatment for COVID-19

By ANGUS McNEICE in London | China Daily Global | Updated: 2020-06-02 10:24
Share
Share - WeChat

The United Kingdom medicines regulator has approved the use of remdesivir, an antiviral drug that is thought to shorten the recovery time for COVID-19 patients.

The drug, which is developed by California-based pharmaceutical company Gilead Sciences, will only be used in adults and adolescents who are hospitalized with severe symptoms of novel coronavirus infection.

Early trials of the drug suggest it can improve the recovery time for patients with severe symptoms of COVID-19 by up to four days.

"This is probably the biggest step forward in the treatment of coronavirus since the crisis began," Health Minister Matt Hancock said at a UK government news conference. "These are very early steps, but we are determined to support the science and back the projects that show promise."

The UK's Medicines and Healthcare products Regulatory Agency, or MHRA, approved the drug under its Early Access to Medicines Scheme, or EAMS.The scheme was created to provide access to promising yet unlicensed drugs for patients with life threatening conditions.

"We are committed to ensuring that patients can have fast access to promising new treatments for COVID-19," said MHRA Chief Executive June Raine. "We will continue to work closely with the Department of Health and Social Care and other healthcare partners on protecting public health in the UK by prioritizing our essential work on clinical trials, access to medicines, and the development of vaccines."

Remdesivir was created in 2009 as a drug to treat hepatitis C. The drug showed limited efficacy against hepatitis, and similarly was ineffective against Ebola virus disease and Marburg virus infections.

However, the drug later showed promising results against several other viruses including coronaviruses.

Remdesivir has been used in several COVID-19 trials since January. Patients given remdesivir had a 31 percent shorter recovery time versus placebo, according to a study in April by the National Institutes of Health, which is an agency of the United States Department of Health.

That trial involved 1,063 hospitalized patients with advanced COVID-19 infection, and the median time to recovery was 11 days for patients on remdesivir, compared with 15 days for those without it.

"This shows fantastic progress," said James Bethell, who is parliamentary Under-Secretary of State for Innovation at the UK Department of Health and Social Care. "As we navigate this unprecedented period, we must be on the front foot of the latest medical advancements, while always ensuring patient safety remains a top priority. The latest, expert scientific advice is at the heart of every decision we make, and we will continue to monitor remdesivir's success in clinical trials across the country to ensure the best results for UK patients."

The drug has also been authorized for emergency use in the US and Japan.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 日韩黄色一级视频 | 97操碰 | av网页在线观看 | 欧美不卡在线 | 超碰99在线 | 亚洲va韩国va欧美va精品 | 羞羞在线| 人人爽人人爽 | 免费在线观看黄色片 | 国产精品视频网站 | 日韩三级精品 | 伊人久久中文字幕 | 深夜福利免费 | 一区二区三区视频在线播放 | 中文字幕在线视频播放 | 国产一级生活片 | 天天草天天草 | 五月婷婷在线视频 | 日本一区二区三区在线视频 | 国产精品羞羞答答 | 亚洲精品1区 | 日韩欧美不卡 | 手机看片国产 | 久久激情小说 | 97国产在线视频 | 久久精品视频网站 | 51av视频| 欧美一级免费看 | 在线一区二区三区 | 精品欧美一区二区精品久久 | 欧美日韩精品在线观看 | a在线视频 | 久热99| 国产精品久久久久久无人区 | 亚洲精品一区二区三 | 日韩精品一二区 | 日韩欧美在线视频 | 欧美日韩毛片 | 午夜视频在线免费观看 | 九九热在线观看视频 | 久久久久久久网 |